Ten-year outcomes: the headline numbers

A decade after OATS, the majority of athletic patients retain good knee function — and the evidence to support that claim is more robust than for most cartilage restoration techniques.

The clearest reference point is the Gudas 2012 randomised controlled trial, the only published ten-year RCT conducted exclusively in athletes. At the ten-year mark, the osteochondral autograft transfer (OAT) group recorded a failure rate of 14%, compared with 38% in the microfracture arm — a statistically significant difference (P < .05). Functional recovery, measured by the ICRS scoring system, was equally encouraging: mean scores rose from 61 before surgery to 93 at ten years (p < 0.01), a shift that represents a substantial, sustained gain in knee function. Tegner activity scores averaged 7 ± 0.4 at the same time point, consistent with continued participation in competitive sport.

The Pareek 2016 systematic review broadens the evidence base beyond a single trial. Across studies with a mean follow-up of 10.2 years — drawn from mixed clinical populations rather than athletes alone — successful outcomes were recorded in 78% of patients. The overall reoperation rate stood at 19%, with a failure rate of 28%. Importantly, IKDC and Lysholm scores improved significantly from pre-operative baseline and remained elevated at the ten-year mark, suggesting the functional benefit is not a short-term phenomenon that erodes over time.

Taken together, both sources point in the same direction: for appropriately selected patients, OATS delivers durable structural and functional results well into the second decade after surgery — a durability that sets it apart from fibrocartilage-producing alternatives.

Getting back to sport — rates, timelines, and what 'return' really means

The return-to-sport figures are among the most practically important numbers in cartilage surgery planning — and for OATS, they hold up well.

Kunze et al.'s 2024 meta-analysis pooled data from 476 professional athletes across cartilage restoration procedures and found an overall return-to-sport rate of 84.3% (95% CI: 75.4%–91.8%) at a mean of 39.9 weeks post-operatively — roughly nine to ten months. That figure, however, is weighted heavily towards microfracture data. OATS-specific evidence tells a more favourable story: Muller et al. reported that 92% of competitive athletes returned to sport at an intermediate-to-high level within six months, and the Gudas 2012 cohort supports a comparable picture in those who received osteochondral autograft transfer.

The consistent finding that tempers this optimism concerns competition level rather than return rate itself. Across six studies that tracked competitive grade post-operatively, every one documented some downward shift — athletes returned to sport, but often to a tier below their pre-injury standard. This is not an outlier result or a complication; it is a reproducible pattern, and one that benefits from an honest conversation during pre-operative planning rather than emerging as a surprise during rehabilitation.

For many athletes, returning to regular high-level activity — even one competitive tier below peak — represents a meaningful functional outcome. Whether that trade-off is acceptable depends on individual priorities and sporting demands, which is precisely the kind of assessment a pre-operative consultation is designed to support.

Who does best — and what raises the risk of re-operation

Patient selection is where OATS outcomes are largely determined before the operation begins.

For the profile most commonly seen in sporting populations — a male athlete under 40 with a small, focal lesion on the femoral condyle (the rounded, weight-bearing surface at the base of the thigh bone), and no previous knee surgery — long-term failure rates may be as low as 12.5%. That is a genuinely reassuring figure, and it reflects the fact that young, active patients with contained lesions are precisely the group this technique was designed to serve.

The picture shifts as certain factors accumulate. Defect size is the strongest individual predictor: lesions at or beyond 3.2 cm² carry a significantly higher risk of failure, according to Pareek et al.'s 2016 systematic review at mean 10.2-year follow-up. Older age at the time of surgery and a history of prior knee procedures each independently increase re-operation risk. Location also matters — patellofemoral lesions (on the kneecap surface and the groove it travels in) fare less well than those sited on the femoral condyle, likely because of the different and more variable loading forces involved.

Where lesion size approaches 4 cm², the mosaicplasty variant — using several smaller plugs arranged to cover a wider area — extends the technical range of autograft transfer. Even so, lesion scope remains the binding constraint on suitability: beyond a certain area, single-stage autograft becomes mechanically insufficient and larger-scale reconstruction may be needed.

Why hyaline cartilage holds longer under athletic load

The reason OATS holds its ground over a decade comes down to what the graft actually is.

OATS transplants mature articular cartilage containing Type II collagen — the same structural protein found in native joint surfaces. Once integrated, the graft behaves mechanically as the original tissue would: resilient under compression, capable of tolerating the repetitive high loads that athletic activity demands.

Microfracture works on an entirely different principle. By puncturing the subchondral bone, it invites bone-marrow progenitor cells to fill the defect — but the tissue that forms is fibrocartilage, built from Type I collagen. Fibrocartilage is a weaker substitute: adequate under moderate demand, but prone to breakdown under the sustained, repetitive loading of sport. Deterioration typically becomes apparent beyond the five-year mark, which explains why studies comparing the two techniques show their sharpest divergence in ten-year data. The Gudas 2012 RCT captures this precisely: a 14% failure rate for osteochondral autograft transfer versus 38% for microfracture at ten years.

The subchondral bone plate — the calcified layer beneath cartilage — is also at risk. Repeated marrow stimulation procedures can damage this layer, narrowing the options if further treatment becomes necessary later.

For patients who will subject the joint to high and repeated mechanical load, restoring the original tissue type is not incidental to the outcome — it is the mechanism behind it. Microfracture still appears in the literature as a historical comparator, but its role as a primary intervention in active patients has substantially declined.

Beyond ten years — and what re-operation actually involves

Keszég's 2022 cohort study, following patients for between ten and 25 years, found no significant decrease in functional scores compared with earlier time points — including at the 20-year mark. That finding suggests the hyaline cartilage graft does not simply hold for a decade and then deteriorate; rather, the tissue appears capable of very long-term structural persistence under joint loading.

The 19% reoperation rate reported in Pareek et al.'s 2016 systematic review (mean 10.2-year follow-up) deserves careful reading. Re-operation does not equate to graft failure. Some of those procedures were minor maintenance interventions — arthroscopic washout or loose-body removal — rather than the full salvage operations the headline figure might imply. The actual failure rate in that review was 28%, and even within that figure, timing, defect characteristics, and prior surgery history shape individual risk considerably.

When OATS does ultimately fail and osteochondral allograft transplantation (OCA) is needed as salvage, the outlook becomes more demanding: subsequent failure has been reported in approximately 16.6% of cases, with an overall reoperation rate of 42.8%. Those numbers make the case for careful selection at the index procedure — not because OATS frequently leads there, but because each additional intervention carries compounding risk.

For a 28-year-old athlete today, the ten-to-25-year dataset is broadly reassuring: a well-selected, well-executed autograft procedure offers the realistic prospect of durable function across the full arc of an active career and into middle age.

Honest gaps: what the evidence still can't tell us

The RCT foundation rests almost entirely on one trial. Gudas 2012 is the only ten-year randomised study conducted exclusively in athletes; while its findings align with systematic review data, generalisation across different sports, ages, and anatomical sites carries that caveat.

The population studied is overwhelmingly male — Kunze et al.'s 2024 meta-analysis found 96.6% male representation, meaning female athletes have essentially no direct long-term RCT data on their outcomes after OATS. Ankle and shoulder lesions, and sports involving sustained high-impact pivoting — basketball, rugby — are similarly underrepresented across the wider literature.

Donor-site morbidity is consistently acknowledged across studies but rarely quantified in long-term follow-up; its precise burden over a decade or more remains difficult to establish from the published record.

"Return to sport" is not a standardised endpoint either. Studies define it differently — return to training, to competition, to pre-injury level — making direct comparisons between reported rates imprecise. The sharper question to put to a surgeon is: return to what, by when, and measured how?

These are the edges of an otherwise consistent evidence base. Knowing them does not weaken the durability case; it refines it. The athlete who enters a consultation understanding which gaps apply to their sex, sport, and lesion site is better placed to calibrate realistic expectations than one reading headline figures in isolation — and better placed to make a decision that will need to hold for the next two decades.